Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Boosting immune responses against leukaemia

Boosting immune responses against leukaemia

In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to vaccinate patients with chronic lymphocytic leukaemia (CLL) against their own cancer.

CLL is the most common blood cancer in New Zealand. The prevalence of CLL increases with age, reaching 1 in 400 in individuals over 70 years old. Although many people with CLL never need treatment, a significant number of patients are diagnosed at a young age or have aggressive disease, exhausting conventional therapies.

Haematologist Dr Robert Weinkove says that bone marrow transplantation is the only curative treatment for CLL and involves replacing the immune system of patients with that of a matched donor.

“Part of the reason that bone marrow transplants work is that the new (donor) immune system recognises the leukaemia cells as foreign and destroys them,” says Dr Weinkove. “This is a good demonstration of how immune therapies can successfully cure established cancers in humans.”

Bone marrow transplants are not without their problems however. Not all patients find a donor; patients are prone to infections for months or even years afterwards; and the treatment itself can be so toxic that it is not suitable for many patients.

“To identify more targeted, low risk immune therapies, we focused on a rare type of immune cell called invariant natural killer T (iNKT) cells,” says Dr Weinkove.

Previous research at the Malaghan Institute and overseas has shown that iNKT cells can be activated by a compound called alpha-galactosylceramide (alpha-GalCer), which was first found in a Japanese marine sponge. This leads to significantly enhanced tumour-specific immune responses.

While iNKT cells are promising targets for immunotherapies, in many cancer patients iNKT cell numbers are either reduced, or the cells do not work properly. Since iNKT cells had never been characterised in patients with CLL before, Dr Weinkove launched a collaborative study between the Wellington Hospital Blood and Cancer Centre and the Malaghan Institute, to determine the number, phenotype and function of iNKT cells in people with this form of leukaemia.

Between 2008 and 2011, Dr Weinkove collected blood samples from 40 patients with CLL and from 30 healthy volunteers of a similar age, from the greater Wellington region. He then undertook a series of laboratory tests to compare the number and function of the iNKT cells from these individuals.

This study, which has recently been published in the open-access, international scientific journal Haematologica, constitutes the first comprehensive investigation of iNKT cell numbers and function in patients with CLL.

“We found that we could detect and isolate iNKT cells from individuals with CLL, and that these cells were able to respond to alpha-GalCer,” says Dr Weinkove. “This is important because it suggests that iNKT cells remain functional in these patients, and that targeting them with treatments like alpha-GalCer might be a way of enhancing their ability to drive anti-cancer immune responses.”

Having shown such great promise in the laboratory, the next step will be to see if these results can be replicated in patients.

“Designing and running safe clinical trials is a major undertaking, but we are exploring a number of ideas, including the possibility of giving alpha-GalCer to patients with blood cancers to boost their immune responses,” says Dr Weinkove.

This work complements the dendritic cell cancer vaccination programme at the Malaghan Institute, further details of which are available at www.malaghan.org.nz.

This research was supported by grants from the Leukaemia & Blood Foundation, Genesis Oncology Trust and NZ Lottery Grants Board. Dr Weinkove also received support from a Genzyme New Investigators Scholarship through the Haematology Society of Australia and New Zealand.
ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Trade Agreements: TPP Minus US Starting To Gain Ground

The Japanese government is picking up the pace on reviving the Trans-Pacific Partnership trade and investment deal, with talks scheduled next month among the 11 countries left in the pact after the withdrawal by the US after the election of president Donald Trump. More>>

ALSO:

PACER:

Prices Up 2.2%: Annual Inflation Highest In Over Five Years

"Rising petrol prices along with the annual rise in cigarette and tobacco tax lifted inflation," prices senior manager Jason Attewell said. "Petrol prices in New Zealand are closely linked to global oil prices, and cigarettes and tobacco taxes rise in the March quarter each year". More>>

ALSO:

Undertaxed? NZ Income Tax Rate Second Lowest Among Developed Nations

New Zealand workers pay the second smallest portion of their income to the government among developed nations and less than half the average ratio of their Organisation for Economic Cooperation and Development peers. More>>

ALSO:

Cyclone Cook: Round Up Of This Week’s Weather

One of the significant impacts this week was flooding due to excessive rainfall amounts. Rainfall amounts topped out at 350mm over the past 60 hours in parts of northwest Nelson, with 200mm+ measurements recorded about Coromandel Peninsula, and between 150-200mm in the Kaimai Ranges. Rainfall amounts of between 30-50mm were commonplace elsewhere. More>>

ALSO:

Earlier: Batten Down The Hatches For Cyclone Cook

Although fast-moving, Cyclone Cook will be destructive and MetService Expert Meteorologists have issued Severe Wind Warnings for the whole of the North Island apart from Northland... More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news